COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma to Present at Upcoming Investor Conferences

06/05/2024 - 14:00

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA [...]

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

06/05/2024 - 14:00

Developed in collaboration with Sanofi. MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the [...]

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

06/05/2024 - 14:00

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

06/05/2024 - 14:00

Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designations for both [...]

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

06/05/2024 - 14:00

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

06/05/2024 - 14:00

Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of [...]

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06/05/2024 - 14:00

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due [...]

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

06/05/2024 - 14:00

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) [...]

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

06/05/2024 - 14:00

In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD [...]

A Message to Our Valued Stakeholders - We're Here for the Long Haul

06/05/2024 - 14:00

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today addresses the recent market fluctuations in its [...]

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

06/05/2024 - 14:00

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

06/05/2024 - 14:00

FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal [...]

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

06/05/2024 - 14:00

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of [...]

Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia

06/05/2024 - 14:00

Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing [...]

GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees

06/05/2024 - 14:00

MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased [...]

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

06/05/2024 - 14:00

POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived [...]

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

06/05/2024 - 13:59

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “ [...]

Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2024 Financial Results on May 15, 2024

06/05/2024 - 13:30

CINCINNATI, May 06, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its [...]

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

06/05/2024 - 13:30

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4. [...]